ChemoMetec raises revenue and EBITDA outlook for fiscal 2026/27
Danish instrument maker ChemoMetec lifted its 2026/27 revenue and EBITDA guidance, citing stronger demand and a leaner cost base.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
According to GlobeNewswire, ChemoMetec has raised its forecast for the 2026/27 financial year. The company credits demand for its instruments, led by the NC-203, which came in above expectations, and a cost base that was lower than planned. Revenue is now expected at DKK 570-605 million, up from the earlier DKK 560-590 million. The EBITDA outlook has also been increased, to between DKK 335 million and DKK 360 million from DKK 330-345 million.
First-quarter figures, due on 5 November, are already known in outline. Revenue rose 28% to DKK 160.0 million from DKK 124.6 million a year earlier. EBITDA reached DKK 100.3 million, giving a margin of 63% against 55% last year.
why it matters
For investors, the main signal is that demand for the company's cell-counting instruments is holding up better than expected, which shows in both sales and profit. A rising EBITDA margin alongside higher sales points to strong operating leverage. The first-quarter report on 5 November will show whether this pace continues.
market impact
ChemoMetec shares: a higher revenue and EBITDA outlook supports investor interest
- ChemoMetec shares pressure up — raised revenue and EBITDA guidance signals strong demand
tags
instruments
sources
- Upgrade of revenue and operating profit guidance — globenewswire.com, 3 November 2026 at 09:21 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗